CDK4 and esophageal squamous cell carcinoma: Given the presence of highly mutation loads in Cyclin D1-CDK4/6-Rb signalling pathway-related molecules of ESCC [9–11], we investigated the effect of CDK4/6 inhibitor SHR6390 in our study.